Celltrion seeks Australian approval for Cosentyx biosimilar
South Korean biopharmaceutical company Celltrion has applied for regulatory approval in Australia for BESEQUMA (secukinumab), its proposed biosimilar to Novartis’ autoimmune disease treatment Cosentyx, as it expands efforts to enter major global pharmaceutical markets.
Celltrion said Thursday that it submitted a marketing authorization application to Australia’s Therapeutic Goods Administration (TGA) for BESEQUMA.
The application covers all indications approved for the reference drug in Australia, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
Cosentyx, developed by Swiss pharmaceutical company Novartis, works by inhibiting interleukin-17A (IL-17A), a protein involved in inflammatory responses. The drug generated $6.6 billion in global sales last year.
Celltrion said a clinical trial involving 172 healthy adults demonstrated pharmacokinetic equivalence between BESEQUMA and the reference drug, with comparable safety and immunogenicity profiles.
The company began seeking regulatory approvals for BESEQUMA in major markets earlier this year, filing applications in Canada in May, South Korea in June, and the United States and Europe in July.
The Australian submission marks another step in its strategy to expand the biosimilar’s global market presence.
Celltrion plans to increase its portfolio of marketed biosimilars from 11 to 18 by 2030.
Its development pipeline includes CT-P53, a proposed biosimilar to Roche’s Ocrevus, and CT-P52, a proposed biosimilar to Eli Lilly’s Taltz, both targeting autoimmune diseases.
In oncology, the company is developing CT-P51, a proposed biosimilar to Merck’s Keytruda, and CT-P44, a proposed biosimilar to Johnson & Johnson’s Darzalex.
“Following applications in the United States, Europe and South Korea, we are accelerating the global expansion of BESEQUMA with our latest submission in Australia,” a Celltrion official said.
“We will continue expanding regulatory filings into additional markets to strengthen the growth prospects of our biosimilar business.”